Recombinant adeno-associated virus (rAAV) is a promising gene delivery vector and has recently been used in patients with hemophilia. One limitation of AAV application is that most humans have experienced wild-type AAV serotype 2 exposure, which frequently generates neutralizing antibodies (NAbs) that may inhibit rAAV2 vector transduction. Employing alternative serotypes of rAAV vectors may circumvent this problem. We investigated the development of NAbs in early childhood by examining sera gathered prospectively from 62 children with hemophilia A, participating in a multi-institutional hemophilia clinical trial (the Joint Outcome Study). Clinical applications in hemophilia therapy have been suggested for serotypes AAV2, AAV5 and AAV8, therefore NAbs against these serotypes were serially assayed over a median follow-up of 4 years. NAbs prevalence increased during early childhood for all serotypes. NAbs against AAV2 (43.5%) were observed more frequently and at higher titers compared with both AAV5 (25.8%) and AAV8 (22.6%). NAbs against AAV5 or AAV8 were rarely observed in the absence of co-prevalent and higher titer AAV2 NAbs, suggesting that NAbs to AAV5 and AAV8 were detected following AAV2 exposure due to partial cross-reactivity of AAV2-directed NAbs. The results may guide rational design of clinical trials using alternative AAV serotypes and suggest that younger patients who are given AAV gene therapy will benefit from the lower prevalence of NAbs.
INTRODUCTION
Hemophilia is caused by the X-linked congenital deficiency of coagulation factor VIII or IX activity and occurs in approximately 1 in 7 500 male births. Patients with severe hemophilia experience spontaneous bleeding into joints, soft tissues and other sites. The standard of care for hemophilia is intravenous clotting factor replacement. 1, 2 Recently, gene therapy has demonstrated sustained success in alleviating the disease phenotype in hemophilic mice and dogs, and transient success in humans. 2, 3 Adeno-associated virus (AAV) is a single-stranded DNA virus and infects both dividing and non-dividing cells. Recombinant AAV (rAAV) vectors can initiate long-term stable transgene expression in rodents and primates with rare host chromosome integration. 4 Currently, 12 naturally occurring serotypes of AAV and several primate isolates have been isolated and studied as gene delivery vehicles. 5, 6 Clinical trials with rAAV2 vectors have been performed in hemophilia B (factor IX deficiency) patients via intramuscular injection or by targeting the liver. 3, 7 No specific side effects were observed from these trials. The most encouraging report thus far involves targeted liver transduction by rAAV2 vectors. After hepatic artery injection of an AAV2 vector expressing factor IX (FIX), FIX activity of greater than 10% of normal was detected in the circulation for 2 weeks before returning to baseline. 3 Over 90% of the adult human population has been infected with wild-type AAV2. In approximately 20-60% of this subpopulation, an adaptive humoral response results in the development and maintenance of antibodies capable of neutralizing subsequent infection by AAV2 (neutralizing antibodies (NAbs)). [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The existence of NAbs can limit rAAV therapeutic applications that rely on systemic vector administration, for example, by interfering with cell surface binding or promoting reticuloendothelial clearance and destruction of AAV vectors. [20] [21] [22] Additionally, previous human studies have observed that NAbs against AAV2 cross-neutralize other serotypes of AAV. 15 This problem is particularly relevant for patients with hemophilia because the most promising treatment relies on vector delivery to the liver through blood circulation. 3, 23, 24 The Joint Outcome Study (JOS) was a multi-institutional prospective clinical trial that randomized boys with hemophilia between 2 therapeutic approaches (preventive or on-demand clotting factor replacement) and followed patients prospectively over 3-5 years; JOS results demonstrating superior joint protection using a preventive approach have been reported previously. 1 Serial blood samples were collected throughout the JOS to examine exposure to viruses, including AAV. In this study, we report the first descriptive analysis that follows a disease cohort longitudinally to examine NAb development and persistence in response to natural AAV exposure. Samples were assayed for NAbs directed against three different serotypes of AAV (AAV2, 5 and 8), each of which represents widely divergent clades of AAV phylogenetically, 6 and each of which has been proposed and/or tested as a potential clinical vector for gene therapy of hemophilia. 3, [23] [24] [25] [26] 
RESULTS
Sixty-two pediatric patients with hemophilia A were followed during the JOS and the characteristics of this population in regard to their underlying bleeding disorder and other demographics have been reported in detail. 1 Serial blood samples from these boys were examined for evidence of neutralizing antibodies to parvovirus including AAV2, AAV5, and AAV8 from the time of enrollment on trial. Patients were enrolled before the onset of recurrent joint bleeding or radiographic evidence of hemophilic joint disease, and were followed until approximately the sixth birthday. The initial blood sample was collected at the time of study enrollment (median 23.5 months old, range 9 month to 40 months) and at least one sample/ patient/year was assayed until the final evaluation (median 70 months of age, range 55 months to 87 months). The follow-up ranged from 33 months to 62 months (median 48 months). A total of 277 samples were analyzed (average 4.5 samples from each patient).
The neutralizing antibody assay employed here has been described previously. 16 Any sample was considered negative, if pre-incubation of the AAV vector with patient serum did not interfere with the capacity of AAV to transduce cells in tissue culture; the lowest dilution of patient serum that resulted in less than 50% transduction of the control was defined as the NAb titer.
Thirty-five boys (56.5%) remained negative for NAbs directed against any of the 3 serotypes during the entire course of the follow-up. In considering the epidemiology of exposure to wild-type AAV in the early childhood years, the earliest positive sample was observed in a patient entering the study at 9 months of age. The prevalence of individuals expressing NAbs at any point during the course of the study as well as the distribution of peak NAb titers directed against each serotype is shown in Figure 1 . NAbs against AAV2 were observed with highest titers and the highest frequency, present in 27 of the 62 subjects (43.5%), compared with AAV5 (16 of 62 subjects, 25.8%) or AAV8 (14 of 62 subjects, 22.6%).
The prevalence of NAbs to AAV2 increased steadily throughout the study period as boys aged (Figures 2 and 3) . Only 16.1% of boys had AAV2 neutralizing antibodies at their study entry blood sample. The prevalence of patients with AAV2 NAbs was 24.2, 33.9 and 38.7% by 3-, 4-and 5-year-old, respectively, and ultimately 43.6% of boys demonstrated AAV2 NAbs by X5 years of age. During the follow-up, 17 patients who were negative at the time of recruitment seroconverted against AAV2, at a median of 38 months. The pattern of seroconversion in these 17 boys (as well as additional subjects who entered the study AAV2 NAb-positive but subsequently showed an acute increase in titer) suggests primary AAV2 infections in this age group (Figure 4) .
Once detected, NAb titer to AAV2 increased or stayed stable throughout the period of follow-up. Resolution of AAV2 NAbs was seen in only one patient (Figure 4) . Clinical data using rAAV vector suggests that low titer NAbs can affect transduction efficiency, with Figure 1 Overall prevalence of seropositive individuals with neutralizing antibody against AAV 2, 5 and 8 and distribution of peak titers. Serial sera samples from subjects were assayed at least yearly throughout a median of 48 months follow-up in early childhood. Sera was defined as positive when a 1:2 dilution of serum inhibited AAV transduction over 50% compared with the control. The percentage of the total population of 62 subjects that demonstrated NAbs for each serotype at some point during the study is shown along with the distribution by range of neutralizating titer for AAV2, AAV5, and AAV8. preclinical animal studies implicating neutralizing titers as low as p1:5. 27-29 At study exit, 19/27 of the AAV2 seropositive patients had a titer of X1:5.
The incidence of NAbs to AAV5 was lower than NAbs to AAV2, but did increase with age over 5 years (Figures 1-3 ). The number of subjects who had AAV5 NAbs at any time point over the course of the study was 25.8% (16 of 62 patients). AAV5 NAbs were detected in only 8% of boys at study entry. Eleven boys who were seronegative at the time of enrollment subsequently seroconverted against AAV5 while on study. The median age for seroconversion was 38 months (Figure 3 ). In contrast to AAV2 NAbs, the peak AAV5 NAb titers were low in many patients in whom they were detected and titers fell over time in many patients. The NAbs resolved completely in 3/15 patients ( Figure 4 ). The results suggest that observed AAV5 neutralization might result from cross-reacting antibodies, raised in response to a primary infection by a different agent (for example, wild-type AAV2) rather than a primary AAV5 infection. At study exit, 9/16 of the AAV5 seropositive subjects had a titer of X1:5.
AAV8-specific NAbs were detected with a lower frequency, with only 3/62 patients (4.8%) having AAV8-specific NAbs at study entry. The overall prevalence was 22.6% (14 of 62 subjects) at any time point over the course of the study (Figures 1 and 3 ). Seroconversion against AAV8 was observed in 11 subjects who had no AAV8 NAb at study entry. In four of these subjects, the NAbs were detected only once at study exit at greater than 60 months of age. The median age for seroconversion was 62 months, that is, later than seroconversion to AAV2. Like AAV5 NAbs, the dynamic pattern of AAV8 NAbs titer was more likely to decrease than to increase during the course of the study, and in this way, contrasted with AAV2 NAbs (Figure 4) . The NAbs resolved completely in 1/15 subjects. At study exit, 10/14 of the AAV8 seropositive patients had a titer of X1:5.
The total number of boys demonstrating NAbs to AAV2, AAV5 and AAV8 at some point during the follow-up was 27 (43.5%), 16 (25.8%) and 14 (22.6%), respectively ( Figure 1 ). The NAb titer against AAV2 was generally higher than that to AAV5 and AAV8. Although no patient developed a NAb titer over 1,000 against AAV5 and AAV8, 7 patients (12.9%) had AAV2 NAb with titer X1000. Examining this phenomenon more closely among the patients with NAbs, the median peak anti-AAV titers were 1:10, 1:8, and 1:8 for AAV2, AAV5 and AAV8, respectively. Nevertheless, very high neutralizing antibody titers were often seen against AAV2, so that the mean peak titers were AAV2 1:608; AAV5 1:47; AAV8 1:56. Additionally, having a high titer (but not a low titer) of AAV2 NAbs was associated with a statistically greater relative risk (RR) of having co-prevalent NAbs to AAV5 and/or AAV8 ( Figure 5 ). Considering all 62 boys in the study, those with a peak AAV2 NAb titer of 41:1000 had a RR¼5 (95% confidence interval (CI) 3.01-8.29) of also having detectable AAV5 NAb and a RR¼9 (CI¼4.23-19.14) of co-prevalent AAV8 NAb. Peak AAV2 NAb titer of 1:100-1:1000 was associated with AAV8 NAb (RR¼5, CI¼3.01-8.29). Although AAV2 Nab 1:5-1:100 was associated with borderline increased risk of AAV5 NAb (RR¼2.26, CI¼1.01-5.07), association of lower AAV2 NAb titers with risk of AAV8 NAb did not achieve significance.
Eleven patients had NAbs to all three AAV serotypes (Table 1) . Except for patient HOU 04, in whom the NAb titer was less than 1:10 to all serotypes, the other ten patients had a much higher NAb titer to AAV2 than to AAV5 or 8, whereas the NAb titer to AAV8 was similar to or a little higher than to AAV5. Figure 4 The dynamic change of NAbs titers over the course of study. Subjects who had NAbs to the given AAV serotype on at least 2 time points were analyzed for dynamic pattern of neutralizing titer. Numbers overlying the bars represent number of individual seropositive subjects displaying the given dynamic pattern. Once detected, NAb titer to AAV2 increased or stayed stable throughout the period of follow-up (in 84% of seropositive individuals) whereas AAV5 and AAV8 NAb titers often decreased or resolved (B40% of individuals positive for these serotypes).
Proportion of subjects with coprevalent NAbs to AAV5 or AAV8 Figure 5 Association of AAV2 NAb titers and co-prevalence of AAV5 or AAV8 NAb Subjects with AAV2 neutralizing antibodies were grouped by distribution of peak anti-AAV2 neutralizing antibody titer (as in Figure 1 ) and examined for co-prevalence of AAV5 and AAV8 neutralization. The proportions of co-prevalent NAbs to AAV5 and AAV8 increased gradually in subjected with higher AAV2 NAb titers. All subjects with AAV2 titers over 1:1000 (8 of 8) had co-prevalent NAbs to AAV5 and 8. Among subjects with AAV2 titers lower than 1:5, co-prevalent NAbs to AAV5 and 8 were present in only 25% (1/4) and 0% (0/4) of subjects, respectively. Antibodies neutralizing AAV serotypes in children C Li et al
To study the co-prevalence of NAbs, all 277 sera samples were examined. NAbs against at least 1 serotype were measured in 136 samples. Of 134 samples with NAb to AAV2, NAb to AAV5 and AAV8 were found in 46 and 28%, respectively. In contrast to this, the 64 samples NAb-positive for AAV5 were coincidentally seropositive for AAV2 in 97% and for AAV8 in 55% of the samples (Table 2 ). AAV8 NAb-positive samples also demonstrated AAV2 neutralization in 96% of samples. Examining these 44 samples that had co-prevalent anti-AAV2 and anti-AAV8 NAbs, the level of the neutralizing activity directed against AAV2 (AAV2 NAb titer) was higher than the level of neutralizing activity directed against AAV8 (AAV8 NAb titer) in 96% of the samples.
DISCUSSION
The Hemophilia Joint Outcome Study (JOD) afforded an opportunity for the first prospective analysis of AAV neutralizing antibody development following childhood exposure in a relevant disease population. The JOS population is of interest because hemophilia is a monogenic disorder that has received a great deal of investigation as a potentially curable disorder with gene therapy. Specifically, human gene therapy trials using AAV2 and AAV8 serotypes for liver-directed correction of hemophilia are being performed, and preclinical approaches have used AAV2, AAV5 and AAV8 in animal models of hemophilia, directing therapy to the liver and to the joints. 3, 23, 24, 26, [30] [31] [32] In addition, the onset of the most common complications of hemophilia (for example, inhibitor antibody formation and hemophilic joint disease) most commonly occur in childhood, so that gene therapy approaches to avoid or treat these complications ideally would be delivered to boys at this age. Boys entered the JOS trial at a very young age (o30 months of age) and regular prospective sample collection was performed for years during early childhood. Although some data collected from cross-sectional population studies exists regarding wild-type AAV2 exposure in childhood, this study afforded the first chance to look at the epidemiology of exposure to other serotypes at this age, in a way that demonstrates dynamic changes during early childhood. During a follow-up of 4 years on this trial, the prevalence of NAbs directed against AAV rose with increasing age in this cohort of 62 boys with hemophilia. The pattern of NAb development and titers strongly suggests that primary infection with AAV2 is common at this age, with the development of neutralizing anti-AAV2 antibodies which persist for years and potentially crossneutralize other AAV serotypes.
Important insight is gained in two related areas. First, within the realm of wild-type AAV biology, this study highlights the epidemiology of exposure to wild-type AAV in early childhood. The second area pertains to the use of rAAV as gene therapy vectors. With regard to the epidemiology of AAV exposure in early childhood, titers as low as 1:2 were reproducible in our assay. Once detected, titers at this level, or higher, persisted in the individual patient rather than being detected intermittently. The earliest age that NAbs against AAV2 were seen in this study was 9 months (enrollment samples of 2 patients). The youngest appearance of NAbs against AAV5 or AAV8 was at 14 months. However, the specificity of the AAV5/AAV8 response is unclear, because these samples also demonstrated co-prevalent AAV2 antibodies with tenfold higher neutralizing titer. Small cross-sectional studies of AAV NAbs in randomly selected pediatric populations performed in the late 1960s have previously demonstrated AAV2 NAbs in the first 3 months of life, consistent with maternal-fetal passage of maternal IgG, followed by a nadir in prevalence in infants around 6-7 months of age. 8, 9, 33 After maturation of the humoral immune system in the first year of life, AAV2 NAbs increased in prevalence in these cross-sectional reports throughout most of the first decade of life.
In our JOS population, the proportion of boys remaining free of any NAbs against AAV at ages 2-6 progressively falls (Figure 3 ). The development of NAbs to AAV (Total of AAV2, AAV5 and AAV8 NAbs) essentially parallels the development of NAbs to AAV2 and appears to be most dependent on exposure to wild-type AAV2. Although boys were twice as likely to enter the study with NAbs to AAV2 as to AAV5 or AAV8, among those initially negative and seroconverting during the follow-up, the median age of seroconversion was 38, 38 and 62 months for AAV2, AAV5, and AAV8, respectively. Between 2 years of age and 5 years of age, the prevalence of AAV5 and AAV8 NAbs does not change significantly, (Figure 2 ) whereas the prevalence of AAV2 NAbs rises. At the final time point at 6 years of age, some increase in the prevalence of NAbs against AAV5 and AAV8 was seen, although, even at this age, the neutralizing titer of anti-AAV8 and anti-AAV5 antibodies was lower than the neutralizing titer of co-prevalent AAV2 antibodies. A striking finding is that, once established, NAbs against AAV2 persist, whereas AAV5 and AAV8 NAbs were transient in some patients. As a result, at no age before the age of 5 years does the JOS population have NAb prevalence of 416% for AAV5 or 412.9% for AAV8.
Examining the existing literature regarding AAV NAbs in childhood, cross-sectional studies of random pediatric populations have measured AAV2 NAbs in 39-58% of children aged similar to our cohort (age 3-6). 8, 9, 33 A single study looking at AAV5 NAbs measured 25-33% in a cohort of 1-to 10-year-old children. 14 Our prospectively, longitudinally captured data are generally consistent with these previous reports. No previous study has specifically examined AAV8 NAbs in children. The prevalence of NAbs to AAV8 in healthy adults has been reported to be 15-40% 10,11 whereas the prevalence during our pediatric cohort follow-up was 22.58%.
A study by Halbert et al, examining a pediatric cystic fibrosis population aged 0-10 years, reported 10.4% AAV2 NAbs and 4.2% AAV5 NAbs, which are strikingly lower than what we measured. 15 Factors that contribute to discrepancies in NAb results between different studies include variations in assay technique and interpretation, for example, the use of (i) different marker genes, following which the measure of neutralized expression of the genes may result in the variations of sensitivity; (ii) different AAV particles per cell and different cell lines used for transduction and (iii) differences in the definition of the dilution of patient sample used to define a minimum titer.
Wild-type AAV is not associated with any clinical disease, and therefore seroconversion in response to wild-type AAV exposure is most relevant in so far as it confers potential interference and Antibodies neutralizing AAV serotypes in children C Li et al neutralization of therapeutic gene delivery by rAAV vectors, in particular, following systemic vector delivery. 19, 21, 34 A positive neutralizing antibody has been defined in the previously published studies (noted above) in a variety of ways, often using 1:20 and higher as the cut-off to define the presence of a neutralizing antibody. Nevertheless, preclinical animal studies suggest that titers as low as 1:5 may be sufficient to effectively eliminate gene delivery using AAV2 serotype vectors, and perhaps other serotypes as well. [27] [28] [29] In light of this data, we chose to highlight the presence of AAV NAbs X1:5 for AAV2, AAV5 and AAV8 in the current study. By the age of exit from the study (4 6 years of age) for the cohort of 62 males, the prevalence of NAbs X1:5 for AAV2, AAV5 and AAV8 was 30.6, 14.5 and 16.1%, respectively. As noted earlier, therapeutic levels of FIX expression following rAAV2 vector hepatic transduction were achieved in a human clinical trial, but were transient. 3 The FIX expression is believed to have been limited by cytotoxic lymphocyte elimination of AAV vector-transduced hepatocytes following memory T-lymphocyte recognition of AAV2 antigenic epitopes from previous exposure to wild-type AAV2. The subjects on the aforementioned trial who apparently demonstrated immunologic responsiveness to AAV2 did so despite very low neutralizing antibody titers against AAV2 (p1:2). The response underscores the importance of understanding the natural history of exposure to wild-type AAV serotypes. For this reason, we chose for this cohort of boys to report the evidence of any seroconversion (X1:2, Figures 1-3 ) and also the evidence for neutralizing antibody titers that may be expected to impede transduction (X1:5, Figure 1) . AAV NAbs that develop as an expected response following rAAV in gene therapy clinical trials have been documented in a prospective fashion; these iatrogenic NAbs typically develop at high titers and persist for years (persisting throughout all available follow-up periods reported to date). 35, 36 The prospective cohort design of the JOS allows a comprehensive study of the dynamics of NAb after wild-type AAV exposure, including patterns of persistence or resolution in individual subjects. These patterns differed for AAV2 NAbs compared with AAV5 NAbs and AAV8 NAbs. Once positive, AAV2 NAbs remained throughout the time on study generally with the titer increasing. In contrast, once positive, AAV5 NAbs and AAV8 NAbs titers tended to be stable or decrease. (Figure 4 ) Considering in addition that AAV5 NAbs and AAV8 NAbs were approximately half as prevalent as AAV2, rAAV5 and rAAV8 gene therapy vectors may be valuable reagents to avoid the effect of pre-existing antibodies against AAV2 in young children.
In our studies, most patients with NAbs to AAV5 or AAV8 had coprevalent NAbs to AAV2, and the titer of NAbs to AAV2 was higher than that to AAV5 and AAV8 (Tables 1 and 2 and Figures 5 and 6 ). Halbert et al reported similar findings, demonstrating that AAV2 NAbs prevalence and titers were higher than AAV5 and AAV6 NAbs in both children and adults. 15 In their study, all AAV6 NAbs positive samples were positive for AAV2 NAbs, and 95% of sera with AAV5 NAbs also had NAbs to AAV2. 15 These and other similar results strongly support the model that individuals originally infected by AAV2 develop NAbs that cross-react with other AAV serotypes. 10, 19 Of the 277 samples assayed, only 2 samples were negative for NAbs against AAV2 but positive for another serotype. (Figure 6 ) In each of these samples (both from the same patient), low titer antibodies against both AAV5 and AAV8 were found. This patient's AAV5 and AAV8 NAbs eventually resolved and persisting AAV2 NAbs developed at 4 years of age. An alternative consideration is that primary infection with a different serotype that we have not examined, for example, AAV1, could boost the AAV2 and other serotype titers and further aggravate cross-reactivity.
Prospectively documenting the increasing prevalence and dynamic patterns of AAV neutralizing antibodies in the JOS cohort provides important information for rational design of clinical trials using AAV vector gene therapy: (i) if NAbs exist, an alternative serotype should be considered and (ii) the earlier in life the better as the likelihood of AAV infection generating NAbs increases with advancing age, neutralizing titers may persist for years, and cross-neutralization of multiple serotypes is common. This understanding may further inform AAV vector technologies such as the use of rational capsid design or DNA shuffling to generate capsid mutants to escape antibody neutralization and enhance transduction. 37, 38 One such mutant designed in our lab has been used in patients with Duchenne muscular dystrophy in a Phase I human clinical trial. 39 
PATIENTS AND METHODS Patients
Sixty-two pediatric patients with hemophilia A were enrolled to the JOS before the onset of recurrent joint bleeding or radiographic evidence of hemophilic joint disease, and were followed until approximately the sixth birthday. At least one serial blood sample/year from each patient was assayed. Blood sera were stored at À80 1C until neutralizing antibody assay. The study was approved by the Institutional Review Boards of the individual JOS study sites as well as the University of North Carolina at Chapel Hill and the University of Colorado, Denver.
Cell culture
Human embryonic kidney 293 cells and human glioblastoma U87MG cells were obtained from ATCC. 293 cells were cultured in DMEM medium with 10% FBS. U87MG cells were incubated in the DMEM + 10% FBS supplemented with 2 mM L-Glutamine and 1% non-essential amino acids. All culture was propagated at 37 1C in a 5% carbon dioxide atmosphere. 293 cells were used for AAV2 and AAV5 NAb analysis. As AAV8 do not transduce 293 cells efficiently, U87MG cells were used for AAV8 target cells. 
Production of AAV vector
All recombinant AAV viruses were generated using the standard triple transfection method using the XX6-80 adenoviral helper plasmid with a packaging plasmid (either AAV2, AAV5 or AAV8) and an ITR plasmid (containing GFP-pTR-EGFP). 40 rAAV/GFP was purified using standard methodology and the physical titer of the different viral preparations was evaluated using dot blot hybridization. 41 
Neutralizing antibody assay
NAbs titer was assayed using methodology described by Moskalenko et al with slight modifications. 17 Briefly, 293 cells or U87MG cells were seeded in a 48-well plate at a density of 10 5 cells/well in 200 ml DMEM containing 10% FBS. The cells were cultured for 3-4 h at 37 1C and allowed to adhere to the well. AAV-GFP (1Â10 8 particles) was mixed with serial twofold dilutions of subject sera (diluted with PBS) and incubated for 2 h at 4 1C in a total volume of 25 ml. The mixture was added to cells in a final volume of 200 ml that contained 4Â10 6 particles of adenovirus dl309 and incubated 24 or 48 h at 37 1C. GFP-expressing cells were counted under a fluorescent microscope. The neutralizing antibody titer was calculated using the highest dilution where the percentage of GFP expressed cells were 50% less than control without sera. The lowest sera dilution was 1:2. Although we have chosen to document a very high level sensitivity, any positive value that was observed at only a single time point and with a titer of less than 1:10 was assumed to be artifactual.
